Novartis Ag (NVS) R&D In Process (2024 - 2026)

Novartis Ag's (NVS) quarterly R&D In Process came in at $11.3 billion in Q1 2026, up 3233.33% quarter-over-quarter from $339.0 million in Q1 2024.

Novartis Ag (NVS) R&D In Process (2024 - 2026) Analysis & Trends

Novartis Ag has disclosed R&D In Process across 2 years of filings, most recently posting $11.3 billion for Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	R&D In Process (Qtr)
1	Gsk	92,316,836.42 Bn	92,316,831.46 Bn	7.76 Bn	-
2	Eli Lilly	983.57 Bn	978.29 Bn	16.22 Bn	584.00 Mn
3	Johnson & Johnson	553.56 Bn	531.50 Bn	15.96 Bn	-
4	AbbVie	383.35 Bn	374.00 Bn	10.78 Bn	744.00 Mn
5	Merck	281.71 Bn	276.06 Bn	12.09 Bn	-
6	Amgen	182.20 Bn	170.16 Bn	5.87 Bn	-
7	Gilead Sciences	153.71 Bn	145.98 Bn	5.52 Bn	107.00 Mn
8	Pfizer	143.75 Bn	130.98 Bn	-1.21 Bn	137.00 Mn
9	Bristol Myers Squibb	109.71 Bn	99.25 Bn	8.07 Bn	94.00 Mn
10	Novartis Ag	108.28 Bn	107.60 Bn	-	11.30 Bn

Download Data

Date	Value
Mar 31, 2026	11.30 Bn
Mar 31, 2024	339.00 Mn